Article Information
History
- July 1, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Elham Alhathli1,3,
- Thomas Julian2,
- Zain Ul Abideen Girach1,
- A A Roger Thompson4,
- Christopher Rhodes6,
- Stefan Gräf7,
- Niamh Errington6,
- Martin R Wilkins6,
- Allan Lawrie6,
- Dennis Wang5,6,8 and
- Johnathan Cooper-Knock1,*
- 1Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK
- 2Division of Evolution, Infection and Genomics, School of Biological Sciences, The University of Manchester, Manchester, UK
- 3Department of Nursing, Faculty of Applied Medical Sciences, Taif University, Taif, Saudi Arabia
- 4Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
- 5Department of Computer Science, University of Sheffield, Sheffield, UK
- 6National Heart and Lung Institute, Imperial College London, London, UK
- 7Department of Respiratory Medicine, University of Cambridge, Cambridge, UK
- 8Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore
- ↵*Correspondence: Corresponding Author j.cooper-knock{at}sheffield.ac.uk
Posted July 01, 2023.
A Mendelian randomization study with clinical follow-up links metabolites to risk and severity of pulmonary arterial hypertension
